중동 및 아프리카 면역 측정-감마 카운터 시장, 제품 유형( 자동 , 수동/반자동), 웰(다중 웰, 단일 웰), 응용 분야( 방사면역 측정 , 핵의학 측정, 기타), 질병 상태( 암 바이오마커 , 감염성 질환, 치료적 약물 모니터링 , 내분비 호르몬, 알레르기, 신생아 선별 검사, 심장 마커 , 자가면역 질환, 기타), 구매 모드(단독 구매, 임대 구매), 최종 사용자(실험실, 병원, 연구 및 학술 기관, 제약 및 생명 공학 회사, 혈액 은행, 기타), 유통 채널(직접 입찰, 제3자 유통업체), 국가(사우디 아라비아, 남아프리카 공화국, UAE, 이스라엘, 쿠웨이트, 이집트 및 중동 및 아프리카의 나머지 지역) 산업 동향 및 2028년까지의 예측.
시장 분석 및 통찰력: 중동 및 아프리카 면역 검정 감마 카운터 시장
중동 및 아프리카 면역 검정 감마 카운터 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 3.9%의 CAGR로 성장하고 있으며 2028년까지 251만 달러에 도달할 것으로 예상된다고 분석합니다. 만성 질환의 유병률 증가와 핵의학의 채택 증가는 예측 기간 동안 시장 수요를 촉진한 주요 요인입니다.
면역 검사는 항체 또는 항원을 사용하여 용액에서 거대 분자 또는 소분자의 존재 또는 농도를 측정하는 생화학적 검사입니다. 생화학적 검사는 "감마 카운터"라고 알려진 장치를 통해 수행됩니다. 감마 카운터는 방사성 핵종에서 방출되는 감마선을 측정하는 기구입니다. 조사 미터와 달리 감마 카운터는 일반적으로 여러 샘플을 자동으로 측정하고 이동시키는 소량의 방사성 물질 샘플을 측정하도록 설계되었습니다. 증가하는 연구 개발 지출, 증가하는 의료 지출, 만성 질환 치료에 대한 환자 인식 증가는 시장에 수익성 있는 성장 기회를 제공할 것으로 예상됩니다. 그러나 감마 카운터의 높은 비용과 감마선 위험은 예측 기간 동안 시장 성장을 제한할 것으로 예상되는 요인입니다.
면역 검정 감마 카운터 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 분석가 브리핑을 위해 저희에게 연락하세요. 저희 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드릴 것입니다.
중동 및 아프리카 면역 측정 감마 카운터 시장 범위 및 시장 규모
Immunoassay gamma counters market is segmented on the basis of product type, well, application, disease condition, purchase mode, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product type, the Middle East and Africa immunoassay-gamma counters market is segmented into automated, manual/semi-automated. In 2021 automated segment is expected to dominate the market as it has higher production rates, increased productivity, and lower operating cost
- On the basis of well, the Middle East and Africa immunoassay-gamma counters market is segmented into multi-well, single-well. In 2021, the multi-well segment is expected to dominate the market because of accurate measurements, and ability to produce higher spectra levels in short period of time.
- On the basis of application, the Middle East and Africa immunoassay-gamma counters market is segmented into radio immunoassays, nuclear medicine assays, others. In 2021, radio immunoassays is expected to dominate the market due to highly specificity and sensitivity
- On the basis of disease condition, the Middle East and Africa immunoassay-gamma counters market is segmented into cancer biomarker, infectious diseases, therapeutic drug monitoring, endocrine hormones, allergy, neonatal screening, cardiac markers, auto immune disease, others. In 2021, the cancer biomarkers segment is expected to dominate the market due to technological advancements, and ability in estimating risk of diseases
- On the basis of purchase mode, the Middle East and Africa immunoassay-gamma counters market is segmented into out-right purchase, rental purchase. In 2021, the out-right purchase segment is expected to dominate the market due to reduced risk, innovation and tax incentives.
- On the basis of end user, the Middle East and Africa immunoassay-gamma counters market is segmented into Laboratory, hospitals, research & academic institutes, pharmaceutical & biotechnology companies, blood banks, others. In 2021, the laboratory segment is expected to dominate the market due to regulatory compliances, repeatability and objectivity
- On the basis of distribution channel, the Middle East and Africa immunoassay-gamma counters market is segmented into direct sales and third party distributors. In 2021, direct tender segment is expected to dominate the market because of a larger number of players in the market and the geographical presence of these market players.
Immunoassay-Gamma Counters Market Country Level Analysis
The immunoassay-gamma counters market is analyzed and market size information is provided on the basis of product type, well, application, disease condition, purchase mode, end user, and distribution channel as referenced above.
The countries covered in the bacteriophages therapy market report are the Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and Rest of Middle East and Africa.
Saudi Arabia is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of stronger customer orientation towards internal users, and direct communication with suppliers.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Product approvals and novelty in diagnosis procedures are boosting the market growth of immunoassay-gamma counters.
Immunoassay gamma counters market also provides you with detailed market analysis for every country growth in bacteriophage therapy industry with drugs sales, impact of advancement, technology and changes in regulatory scenarios with their support for the immunoassay-gamma counters market. The data is available for historic period 2011 to 2019.
Competitive Landscape and Immunoassay-Gamma Counters Market Share Analysis
Immunoassay gamma counters market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to immunoassay-gamma counters market.
The major companies operating in the immunoassay-gamma counters market are Hidex Oy, Perkin Elmer Inc, Berthold Technologies GmbH & Co. KG, ENERSYS Co. Ltd, Shinjin Medics Inc, LabLogic Systems Ltd, among others.
Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the immunoassay-gamma counters market.
For instance,
- In July 2021, PerkinElmer Inc. announced that the company is further looking to expand their footprints in India by relying on innovative products. The new products will be launched in various streams such as science, pharma, and food testing. This has helped the company to expand its global presence
협력, 제품 출시, 사업 확장, 수상 및 인정, 합작 투자 및 시장 참여자의 기타 전략은 면역 검정 감마 카운터 시장에서 회사 시장을 강화하고 있으며, 이는 조직이 면역 검정 감마 카운터에 대한 제공을 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTES FIVE FORCES
5 REGULATORY GUIDELINES FOR IMMUNOASSAY-GAMMA COUNTERS
5.1 U.S. REGULATORY GUIDELINES FOR IMMUNOASSAYS-GAMMA COUNTERS
5.2 EUROPE REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS
5.3 JAPAN REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS
5.4 CHINA REGULATORY GUIDELINE FOR IMMUNOASSAY-GAMMA COUNTERS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN PREVALENCE OF CHRONIC DISEASES
6.1.2 PRODUCT APPROVAL
6.1.3 INCREASE IN ADOPTION OF NUCLEAR MEDICINE
6.1.4 NOVELTY IN DIAGNOSIS PROCEDURES
6.1.5 UPGRADING GAMMA TECHNOLOGY
6.2 RESTRAINTS
6.2.1 HIGH COST OF GAMMA COUNTER
6.2.2 RISK OF GAMMA RADIATION
6.2.3 STRINGENT REGULATION OF CLINICAL USE OF GAMMA COUNTER
6.2.4 PRODUCT RECALL
6.3 OPPORTUNITIES
6.3.1 GROWING RESEARCH AND DEVELOPMENT EXPENDITURE
6.3.2 INCREASE IN HEALTHCARE EXPENDITURE
6.3.3 RISE IN PATIENTS AWARENESS TOWARDS CHRONIC DISEASE TREATMENT
6.4 CHALLENGES
6.4.1 CHALLENGES IN USING GAMMA COUNTER
6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
7 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET
7.1 IMPACT ON THE PRICE
7.2 IMPACT ON DEMAND
7.3 IMPACT ON SUPPLY
7.4 STRATEGIC INITIATIVES BY MANUFACTURERS
7.5 CONCLUSION
8 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 AUTOMATED
8.2.1 RADIOIMMUNOASSAYS
8.2.1.1 RIA
8.2.1.2 IRMA
8.2.2 NUCLEAR MEDICINE ASSAYS
8.2.2.1 GFR (Glomerular FILTRATION RATE)
8.2.2.2 Gamma glutamyl transferase (ggt)
8.2.2.3 red cell mass and plasma volume test
8.2.2.4 THE SCHILLING TEST
8.2.2.5 others
8.2.3 OTHERS
8.3 MANUAL/SEMI-AUTOMATED
8.3.1 RADIOIMMUNOASSAYS
8.3.1.1 RIA
8.3.1.2 IRMA
8.3.2 NUCLEAR MEDICINE ASSAYS
8.3.2.1 GFR (Glomerular FILTRATION RATE)
8.3.2.2 Gamma glutamyl transferase (ggt)
8.3.2.3 red cell mass and plasma volume test
8.3.2.4 THE SCHILLING TEST
8.3.2.5 others
8.3.3 OTHERS
9 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL
9.1 OVERVIEW
9.2 MULTI-WELL
9.3 SINGLE-WELL
10 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 RADIO IMMUNOASSAYS
10.2.1 RIA
10.2.2 IRMA
10.3 NUCLEAR MEDICINE ASSAY
10.3.1 GFR (GLOMERULAR FILTRATION RATE)
10.3.2 GAMMA-GLUTAMYL TRANSFERASE
10.3.3 RED CELL MASS AND PLASMA VOLUME TEST
10.3.4 THE SCHILLING TEST
10.3.5 OTHERS
10.4 OTHERS
11 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION
11.1 OVERVIEW
11.2 CANCER BIOMARKERS
11.2.1 CARBOHYDRATE ANTIGEN 125 (CA125)
11.2.2 CARBOHYDRATE ANTIGEN 19-9
11.2.3 CARCINO EMBRYONIC ANTIGEN
11.2.4 ALPHA-FETOPROTEIN
11.2.5 OTHERS
11.3 INFECTIOUS DISEASES
11.4 THERAPEUTIC DRUG MONITORING
11.5 ENDOCRINE HORMONES
11.6 ALLERGY
11.7 NEONATAL SCREENING
11.8 CARDIAC MARKERS
11.9 AUTOIMMUNE DISEASE
11.1 OTHERS
12 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE
12.1 OVERVIEW
12.2 OUTRIGHT PURCHASE
12.3 RENTAL PURCHASE
13 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 THIRD PARTY DISTRIBUTORS
14 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 LABORATORY
14.4 BLOOD BANKS
14.5 RESEARCH AND ACADEMIC INSTITUTES
14.6 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
14.7 OTHERS
15 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY GEOGRAPHY
15.1 MIDDLE EAST & AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SAUDI ARABIA
15.1.3 U.A.E.
15.1.4 ISRAEL
15.1.5 EGYPT
15.1.6 REST OF MIDDLE EAST & AFRICA
16 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PERKINELMER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 BRETHOLD TECHNOLOGIES GMBH & CO.KG
18.2.1 COMPANY SNAPSHOT
18.2.2 COMPANY SHARE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENTS
18.3 LABLOGIC SYSTEMS LTD.
18.3.1 COMPANY SNAPSHOT
18.3.2 COMPANY SHARE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENT
18.4 SHIN JIN MEDICS INC.
18.4.1 COMPANY SNAPSHOT
18.4.2 COMPANY SHARE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENTS
18.5 HIDEX OY
18.5.1 COMPANY SNAPSHOT
18.5.2 COMPANY SHARE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENTS
18.6 LABORATORY TECHNOLOGIES. INC.
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 ENERSYS, CO.LTD.
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENTS
18.8 MIRION TECHNOLOGIES (CAPINTEC),INC.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
표 목록
TABLE 1 NUMBER OF PEOPLE WITH DIABETES (MILLION) AMONG AGES 20–79 YEARS
TABLE 2 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
TABLE 3 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA MANUAL/SEMI-AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA MULTI-WELL IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA SINGLE-WELL IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA RADIO IMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA RADIO IMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA NUCLEAR MEDICINE ASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA INFECTIOUS DISEASES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA THERAPEUTIC DRUG MONITORING IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA ENDOCRINE HORMONES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ALLERGY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA NEONATAL SCREENING IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA CARDIAC MAKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA AUTO IMMUNE DISEASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA OUTRIGHT PURCHASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA RENTAL PURCHASE IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY REGION, 2015-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA DIRECT TENDER IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA THIRD PARTY DISTRIBUTORS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA HOSPITALS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA LABORATORY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA BLOOD BANKS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 20152028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA RESEARCH AND ACADEMIC INSTITUTES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 44 OTHERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY COUNTRY, 2015-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE , 2015-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT, TYPE 2015-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA MANUAL/SEMI AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015 -2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE , 2015-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT, TYPE 2015-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA MANUAL/SEMI AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015 -2028 (USD MILLION)
TABLE 67 SOUTH AFRICA RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 72 SOUTH AFRICA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 73 SOUTH AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 77 SOUTH AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE , 2015-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT, TYPE 2015-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA MANUAL/SEMI AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015 -2028 (USD MILLION)
TABLE 83 SAUDI ARABIA RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 91 SAUDI ARABIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 92 SAUDI ARABIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 94 U.A.E. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE , 2015-2028 (USD MILLION)
TABLE 95 U.A.E. AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 96 U.A.E. RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 97 U.A.E. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT, TYPE, 2015-2028 (USD MILLION)
TABLE 98 U.A.E. MANUAL/SEMI AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015 -2028 (USD MILLION)
TABLE 99 U.A.E. RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 100 U.A.E. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 101 U.A.E. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 102 U.A.E. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 103 U.A.E. RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 104 U.A.E. NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 105 U.A.E. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 106 U.A.E. CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 107 U.A.E. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 108 U.A.E. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 109 U.A.E. IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 110 ISRAEL IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE , 2015-2028 (USD MILLION)
TABLE 111 ISRAEL AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 112 ISRAEL RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 113 ISRAEL NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT, TYPE 2015-2028 (USD MILLION)
TABLE 114 ISRAEL MANUAL/SEMI AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015 -2028 (USD MILLION)
TABLE 115 ISRAEL RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 116 ISRAEL NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 117 ISRAEL IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 118 ISRAEL IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 119 ISRAEL RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 120 ISRAEL NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 121 ISRAEL IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 122 ISRAEL CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 123 ISRAEL IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 124 ISRAEL IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 125 ISRAEL IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 126 EGYPT IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE , 2015-2028 (USD MILLION)
TABLE 127 EGYPT AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 128 EGYPT RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 129 EGYPT NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT, TYPE 2015-2028 (USD MILLION)
TABLE 130 EGYPT MANUAL/SEMI AUTOMATED IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015 -2028 (USD MILLION)
TABLE 131 EGYPT RADIOIMMUNOASSAY IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 132 EGYPT NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY GAMMA COUNTERS MARKET, BY PRODUCT TYPE, 2015-2028 (USD MILLION)
TABLE 133 EGYPT IMMUNOASSAY-GAMMA COUNTERS MARKET, BY WELL, 2015-2028 (USD MILLION)
TABLE 134 EGYPT IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 135 EGYPT RADIOIMMUNOASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 136 EGYPT NUCLEAR MEDICINE ASSAYS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY APPLICATION, 2015-2028 (USD MILLION)
TABLE 137 EGYPT IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 138 EGYPT CANCER BIOMARKERS IN IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISEASE CONDITION, 2015-2028 (USD MILLION)
TABLE 139 EGYPT IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PURCHASE MODE, 2015-2028 (USD MILLION)
TABLE 140 EGYPT IMMUNOASSAY-GAMMA COUNTERS MARKET, BY END USER, 2015-2028 (USD MILLION)
TABLE 141 EGYPT IMMUNOASSAY-GAMMA COUNTERS MARKET, BY DISTRIBUTION CHANNEL, 2015-2028 (USD MILLION)
TABLE 142 REST OF MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET, BY PRODUCT TYPE , 2015-2028 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: APPLICATION COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SEGMENTATION
FIGURE 12 INCREASE IN PREVALENCE OF CHRONIC DISEASES AND GROWING USE OF NUCLEAR MEDICINE IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 AUTOMATED IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET
FIGURE 15 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS
FIGURE 16 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2020
FIGURE 17 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, 2021-2028 (USD MILLION)
FIGURE 18 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, CAGR (2021-2028)
FIGURE 19 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2020
FIGURE 21 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, 2021-2028 (USD MILLION)
FIGURE 22 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, CAGR (2021-2028)
FIGURE 23 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY WELL, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2020
FIGURE 25 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 26 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, CAGR (2021-2028)
FIGURE 27 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY APPLICATION, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, 2020
FIGURE 29 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY DISEASE CONDITION, 2021-2028 (USD MILLION)
FIGURE 30 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, CAGR (2021-2028)
FIGURE 31 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISEASE CONDITION, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2020
FIGURE 33 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, 2021-2028 (USD MILLION)
FIGURE 34 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, CAGR (2021-2028)
FIGURE 35 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY PURCHASE MODE, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2020
FIGURE 37 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 38 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 39 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2020
FIGURE 41 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, 2021-2028 (USD MILLION)
FIGURE 42 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, CAGR (2021-2028)
FIGURE 43 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET : BY END USER, LIFELINE CURVE
FIGURE 44 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: SNAPSHOT (2020)
FIGURE 45 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2020)
FIGURE 46 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY COUNTRY (2020 & 2028
FIGURE 48 MIDDLE EAST & AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: BY PRODUCT TYPE (2021 &2028)
FIGURE 49 MIDDLE EAST AND AFRICA IMMUNOASSAY-GAMMA COUNTERS MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
